Cargando…

Ketamine treatment for depression: qualitative study exploring patient views

BACKGROUND: Ketamine is a new and promising treatment for depression but comes with challenges to implement because of its potential for abuse. AIMS: We sought the views of patients to inform policy and practical decisions about the clinical use of ketamine before large-scale roll-out is considered....

Descripción completa

Detalles Bibliográficos
Autores principales: Jilka, Sagar, Odoi, Clarissa Mary, Wilson, Emma, Meran, Sazan, Simblett, Sara, Wykes, Til
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058884/
https://www.ncbi.nlm.nih.gov/pubmed/33427156
http://dx.doi.org/10.1192/bjo.2020.165
_version_ 1783681101224476672
author Jilka, Sagar
Odoi, Clarissa Mary
Wilson, Emma
Meran, Sazan
Simblett, Sara
Wykes, Til
author_facet Jilka, Sagar
Odoi, Clarissa Mary
Wilson, Emma
Meran, Sazan
Simblett, Sara
Wykes, Til
author_sort Jilka, Sagar
collection PubMed
description BACKGROUND: Ketamine is a new and promising treatment for depression but comes with challenges to implement because of its potential for abuse. AIMS: We sought the views of patients to inform policy and practical decisions about the clinical use of ketamine before large-scale roll-out is considered. METHOD: This qualitative study used three focus groups and three validation sessions from 14 patients with prior diagnoses of depression but no experience of ketamine treatment. Focus groups explored their views about clinical use of ketamine and the best way for ketamine to be administered and monitored. The qualitative data were analysed by three service-user researchers using thematic analysis. RESULTS: Five themes were generated: changing public perceptions, risks, monitoring, privacy and data protection, and practical aspects. Participants were conscious of the stigma attached to ketamine as a street drug and wanted better public education, and evidence on the safety of ketamine after long-term use. They felt that monitoring was required to provide evidence for ketamine's safe use and administration, but there were concerns about the misuse of this information. Practical aspects included discussions about treatment duration, administration and accessibility (for example who would receive it, under what criteria and how). CONCLUSIONS: Patients are enthusiastic about ketamine treatment but need more information before national roll-out. The wider societal impact of ketamine treatment also needs to be considered and patients need to be part of any future roll-out to ensure its success.
format Online
Article
Text
id pubmed-8058884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-80588842021-05-04 Ketamine treatment for depression: qualitative study exploring patient views Jilka, Sagar Odoi, Clarissa Mary Wilson, Emma Meran, Sazan Simblett, Sara Wykes, Til BJPsych Open Papers BACKGROUND: Ketamine is a new and promising treatment for depression but comes with challenges to implement because of its potential for abuse. AIMS: We sought the views of patients to inform policy and practical decisions about the clinical use of ketamine before large-scale roll-out is considered. METHOD: This qualitative study used three focus groups and three validation sessions from 14 patients with prior diagnoses of depression but no experience of ketamine treatment. Focus groups explored their views about clinical use of ketamine and the best way for ketamine to be administered and monitored. The qualitative data were analysed by three service-user researchers using thematic analysis. RESULTS: Five themes were generated: changing public perceptions, risks, monitoring, privacy and data protection, and practical aspects. Participants were conscious of the stigma attached to ketamine as a street drug and wanted better public education, and evidence on the safety of ketamine after long-term use. They felt that monitoring was required to provide evidence for ketamine's safe use and administration, but there were concerns about the misuse of this information. Practical aspects included discussions about treatment duration, administration and accessibility (for example who would receive it, under what criteria and how). CONCLUSIONS: Patients are enthusiastic about ketamine treatment but need more information before national roll-out. The wider societal impact of ketamine treatment also needs to be considered and patients need to be part of any future roll-out to ensure its success. Cambridge University Press 2021-01-11 /pmc/articles/PMC8058884/ /pubmed/33427156 http://dx.doi.org/10.1192/bjo.2020.165 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Papers
Jilka, Sagar
Odoi, Clarissa Mary
Wilson, Emma
Meran, Sazan
Simblett, Sara
Wykes, Til
Ketamine treatment for depression: qualitative study exploring patient views
title Ketamine treatment for depression: qualitative study exploring patient views
title_full Ketamine treatment for depression: qualitative study exploring patient views
title_fullStr Ketamine treatment for depression: qualitative study exploring patient views
title_full_unstemmed Ketamine treatment for depression: qualitative study exploring patient views
title_short Ketamine treatment for depression: qualitative study exploring patient views
title_sort ketamine treatment for depression: qualitative study exploring patient views
topic Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058884/
https://www.ncbi.nlm.nih.gov/pubmed/33427156
http://dx.doi.org/10.1192/bjo.2020.165
work_keys_str_mv AT jilkasagar ketaminetreatmentfordepressionqualitativestudyexploringpatientviews
AT odoiclarissamary ketaminetreatmentfordepressionqualitativestudyexploringpatientviews
AT wilsonemma ketaminetreatmentfordepressionqualitativestudyexploringpatientviews
AT meransazan ketaminetreatmentfordepressionqualitativestudyexploringpatientviews
AT simblettsara ketaminetreatmentfordepressionqualitativestudyexploringpatientviews
AT wykestil ketaminetreatmentfordepressionqualitativestudyexploringpatientviews